The 36-month beta value for INBS is also noteworthy at 4.84. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for INBS is 2.82M, and at present, short sellers hold a 2.61% of that float. The average trading volume of INBS on May 08, 2024 was 1.67M shares.
INBS) stock’s latest price update
The stock of Intelligent Bio Solutions Inc (NASDAQ: INBS) has increased by 16.53 when compared to last closing price of 2.48.Despite this, the company has seen a gain of 7.43% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-26 that NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City.
INBS’s Market Performance
Intelligent Bio Solutions Inc (INBS) has experienced a 7.43% rise in stock performance for the past week, with a -23.14% drop in the past month, and a -5.25% drop in the past quarter. The volatility ratio for the week is 12.04%, and the volatility levels for the past 30 days are at 10.73% for INBS. The simple moving average for the past 20 days is 1.72% for INBS’s stock, with a -63.43% simple moving average for the past 200 days.
INBS Trading at -23.76% from the 50-Day Moving Average
After a stumble in the market that brought INBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.56% of loss for the given period.
Volatility was left at 10.73%, however, over the last 30 days, the volatility rate increased by 12.04%, as shares sank -20.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.03% lower at present.
During the last 5 trading sessions, INBS rose by +7.43%, which changed the moving average for the period of 200-days by -89.66% in comparison to the 20-day moving average, which settled at $2.80. In addition, Intelligent Bio Solutions Inc saw -28.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INBS starting from Simeonidis Harry, who purchase 50 shares at the price of $1.85 back on Sep 01 ’23. After this action, Simeonidis Harry now owns 4,180 shares of Intelligent Bio Solutions Inc, valued at $92 using the latest closing price.
Simeonidis Harry, the CEO of Intelligent Bio Solutions Inc, purchase 100 shares at $1.92 during a trade that took place back on Aug 31 ’23, which means that Simeonidis Harry is holding 4,130 shares at $192 based on the most recent closing price.
Stock Fundamentals for INBS
Current profitability levels for the company are sitting at:
- -3.93 for the present operating margin
- 0.21 for the gross margin
The net margin for Intelligent Bio Solutions Inc stands at -5.45. The total capital return value is set at -2.65. Equity return is now at value -196.52, with -99.70 for asset returns.
Based on Intelligent Bio Solutions Inc (INBS), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -6.74. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is -44.83.
Currently, EBITDA for the company is -7.46 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 3.33. The receivables turnover for the company is 4.46for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.57.
Conclusion
In summary, Intelligent Bio Solutions Inc (INBS) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
